Pharmanovia Collaborates with Lindis Biotech to Commercialize Catumaxomab for Treating Malignant Ascites
Shots:
- Pharmanovia has entered into a new licensing agreement with Lindis Biotech for the commercialization of catumaxomab to treat malignant ascites
- Pharmanovia secured exclusive rights to commercialize catumaxomab, a trifunctional bi-specific mAb for intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas, ineligible for further systemic therapy
- Catumaxomab was granted with the CHMP’s positive opinion in Oct 2024, with the EC’s marketing authorization expected by YE’24
Ref: Businesswire | Image: Pharmanovia & Lindis Biotech
Related News:- Stealth BioTherapeutics Entered into an Exclusive License Agreement with Pharmanovia to Commercialize Elamipretide for Barth Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
